Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA methylation-based estimator of blood telomere length (DNAmTL) outperforms qPCR-based telomere length in reflecting clinical and sociodemographic factors in people with HIV infection.

Clinical epigenetics·2026
Same author

Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.

International journal of antimicrobial agents·2026
Same author

Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations.

The Journal of antimicrobial chemotherapy·2026
Same author

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results from the VOLVER Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Effectiveness and Safety of COVID-19 mRNA Vaccines in Children 6-17 Years Old: A Population-based Study in Madrid.

The Pediatric infectious disease journal·2025
Same author

How recent is recent? Retrospective analysis of suspiciously timeless citations.

BMJ (Clinical research ed.)·2025

Related Experiment Video

Updated: Jun 6, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Protease inhibitor monotherapy.

Ignacio Pérez-Valero1, Jose R Arribas

  • 1Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ. Madrid, Spain.

Current Opinion in Infectious Diseases
|December 15, 2010
PubMed
Summary

Boosted protease inhibitor monotherapy can maintain HIV suppression in many patients with minimal resistance risk. However, its precise role in HIV treatment remains undefined, with slightly lower efficacy than dual nucleoside regimens.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: Jun 6, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Boosted protease inhibitor monotherapy is an evolving strategy for maintaining HIV virological suppression.
  • Previous research primarily focused on lopinavir/ritonavir, showing slightly inferior efficacy compared to standard triple therapy.
  • Recent trials investigated darunavir/ritonavir, also indicating a slight decrease in efficacy for maintenance therapy.

Purpose of the Study:

  • To review recent data on boosted protease inhibitor monotherapy for maintaining HIV virological suppression.
  • To assess the efficacy, safety, and resistance profiles of this therapeutic approach.

Main Methods:

  • Review of clinical trials, including MONET and MONOI, evaluating boosted protease inhibitor monotherapy.
  • Analysis of efficacy, virological suppression, resistance development, and specific outcomes like fat recovery and drug penetration.

Main Results:

  • Darunavir/ritonavir monotherapy demonstrated slightly lower efficacy than dual nucleoside regimens but with minimal risk of resistance.
  • Patients failing monotherapy can be re-suppressed effectively, retaining therapeutic options.
  • MONOI trial indicated limb fat recovery and good seminal fluid penetration with darunavir/ritonavir.
  • Conflicting data exist regarding central nervous system protection from HIV replication.

Conclusions:

  • There is no current consensus on the role of boosted protease inhibitor monotherapy in HIV treatment.
  • While effective for maintaining suppression in many patients without significant resistance risk, its exact place in therapy is still under investigation.
  • Further research is needed, particularly for atazanavir/ritonavir combinations.